QIAGEN N.V. (QGEN) Stock Fundamental Analysis
NYSE:QGEN - New York Stock Exchange, Inc. - NL0015002CX3 - Common Stock - Currency: USD
Taking everything into account, QGEN scores 6 out of 10 in our fundamental rating. QGEN was compared to 57 industry peers in the Life Sciences Tools & Services industry. While QGEN has a great health rating, its profitability is only average at the moment. QGEN is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
QGEN had positive earnings in the past year.
In the past year QGEN had a positive cash flow from operations.
Each year in the past 5 years QGEN has been profitable.
In the past 5 years QGEN always reported a positive cash flow from operatings.
1.2 Ratios
QGEN's Return On Assets of 1.47% is fine compared to the rest of the industry. QGEN outperforms 70.18% of its industry peers.
QGEN's Return On Equity of 2.34% is fine compared to the rest of the industry. QGEN outperforms 71.93% of its industry peers.
QGEN has a better Return On Invested Capital (7.09%) than 84.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.47% | ||
| ROE | 2.34% | ||
| ROIC | 7.09% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
QGEN's Profit Margin of 4.23% is fine compared to the rest of the industry. QGEN outperforms 73.68% of its industry peers.
QGEN's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 24.85%, QGEN belongs to the top of the industry, outperforming 94.74% of the companies in the same industry.
QGEN's Operating Margin has declined in the last couple of years.
QGEN's Gross Margin of 63.65% is amongst the best of the industry. QGEN outperforms 91.23% of its industry peers.
In the last couple of years the Gross Margin of QGEN has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.85% | ||
| PM (TTM) | 4.23% | ||
| GM | 63.65% |
OM growth 3Y-29.81%
OM growth 5Y-13.17%
PM growth 3Y-42.96%
PM growth 5YN/A
GM growth 3Y-8.78%
GM growth 5Y-5.78%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so QGEN is destroying value.
There is no outstanding debt for QGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
QGEN has an Altman-Z score of 3.89. This indicates that QGEN is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.89, QGEN is in the better half of the industry, outperforming 71.93% of the companies in the same industry.
The Debt to FCF ratio of QGEN is 2.77, which is a good value as it means it would take QGEN, 2.77 years of fcf income to pay off all of its debts.
QGEN's Debt to FCF ratio of 2.77 is amongst the best of the industry. QGEN outperforms 84.21% of its industry peers.
QGEN has a Debt/Equity ratio of 0.38. This is a healthy value indicating a solid balance between debt and equity.
QGEN has a Debt to Equity ratio (0.38) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.38 | ||
| Debt/FCF | 2.77 | ||
| Altman-Z | 3.89 |
ROIC/WACC1
WACC7.1%
2.3 Liquidity
QGEN has a Current Ratio of 3.61. This indicates that QGEN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.61, QGEN is in line with its industry, outperforming 59.65% of the companies in the same industry.
QGEN has a Quick Ratio of 3.09. This indicates that QGEN is financially healthy and has no problem in meeting its short term obligations.
QGEN has a Quick ratio (3.09) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.61 | ||
| Quick Ratio | 3.09 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 3.45% over the past year.
QGEN shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.09% yearly.
Looking at the last year, QGEN shows a small growth in Revenue. The Revenue has grown by 0.66% in the last year.
Measured over the past years, QGEN shows a small growth in Revenue. The Revenue has been growing by 5.32% on average per year.
EPS 1Y (TTM)3.45%
EPS 3Y-7.11%
EPS 5Y8.09%
EPS Q2Q%10.91%
Revenue 1Y (TTM)0.66%
Revenue growth 3Y-4.22%
Revenue growth 5Y5.32%
Sales Q2Q%2.36%
3.2 Future
Based on estimates for the next years, QGEN will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.82% on average per year.
QGEN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.35% yearly.
EPS Next Y7.19%
EPS Next 2Y8.36%
EPS Next 3Y9.1%
EPS Next 5Y9.82%
Revenue Next Year5.1%
Revenue Next 2Y5.92%
Revenue Next 3Y8.59%
Revenue Next 5Y8.35%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 18.07, which indicates a rather expensive current valuation of QGEN.
92.98% of the companies in the same industry are more expensive than QGEN, based on the Price/Earnings ratio.
QGEN is valuated rather cheaply when we compare the Price/Earnings ratio to 29.63, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 16.86, which indicates a correct valuation of QGEN.
Based on the Price/Forward Earnings ratio, QGEN is valued cheaply inside the industry as 91.23% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.68, QGEN is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.07 | ||
| Fwd PE | 16.86 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, QGEN is valued cheaply inside the industry as 94.74% of the companies are valued more expensively.
QGEN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. QGEN is cheaper than 94.74% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.02 | ||
| EV/EBITDA | 11.63 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of QGEN may justify a higher PE ratio.
PEG (NY)2.51
PEG (5Y)2.23
EPS Next 2Y8.36%
EPS Next 3Y9.1%
5. Dividend
5.1 Amount
QGEN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
39.57
+1 (+2.59%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners63.64%
Inst Owner Change-7.07%
Ins Owners0.41%
Ins Owner ChangeN/A
Market Cap8.55B
Analysts78.18
Price Target51.91 (31.19%)
Short Float %1.21%
Short Ratio2.28
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.67%
Min EPS beat(2)-3.85%
Max EPS beat(2)0.51%
EPS beat(4)3
Avg EPS beat(4)0.41%
Min EPS beat(4)-3.85%
Max EPS beat(4)2.78%
EPS beat(8)5
Avg EPS beat(8)0.89%
EPS beat(12)9
Avg EPS beat(12)4.08%
EPS beat(16)13
Avg EPS beat(16)5.02%
Revenue beat(2)0
Avg Revenue beat(2)-0.97%
Min Revenue beat(2)-1.92%
Max Revenue beat(2)-0.02%
Revenue beat(4)0
Avg Revenue beat(4)-1.29%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)-0.02%
Revenue beat(8)0
Avg Revenue beat(8)-1.08%
Revenue beat(12)4
Avg Revenue beat(12)-0.09%
Revenue beat(16)7
Avg Revenue beat(16)0.75%
PT rev (1m)-0.12%
PT rev (3m)1.69%
EPS NQ rev (1m)1.78%
EPS NQ rev (3m)2.56%
EPS NY rev (1m)0.55%
EPS NY rev (3m)0.85%
Revenue NQ rev (1m)-3.09%
Revenue NQ rev (3m)-5.12%
Revenue NY rev (1m)-0.42%
Revenue NY rev (3m)-0.8%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.07 | ||
| Fwd PE | 16.86 | ||
| P/S | 4.32 | ||
| P/FCF | 17.02 | ||
| P/OCF | 12.69 | ||
| P/B | 2.4 | ||
| P/tB | 10.2 | ||
| EV/EBITDA | 11.63 |
EPS(TTM)2.19
EY5.53%
EPS(NY)2.35
Fwd EY5.93%
FCF(TTM)2.32
FCFY5.87%
OCF(TTM)3.12
OCFY7.88%
SpS9.16
BVpS16.51
TBVpS3.88
PEG (NY)2.51
PEG (5Y)2.23
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.47% | ||
| ROE | 2.34% | ||
| ROCE | 9.55% | ||
| ROIC | 7.09% | ||
| ROICexc | 9.14% | ||
| ROICexgc | 28.87% | ||
| OM | 24.85% | ||
| PM (TTM) | 4.23% | ||
| GM | 63.65% | ||
| FCFM | 25.39% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-29.81%
OM growth 5Y-13.17%
PM growth 3Y-42.96%
PM growth 5YN/A
GM growth 3Y-8.78%
GM growth 5Y-5.78%
F-Score7
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.38 | ||
| Debt/FCF | 2.77 | ||
| Debt/EBITDA | 1.93 | ||
| Cap/Depr | 84.24% | ||
| Cap/Sales | 8.66% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 96.93% | ||
| Profit Quality | 600.91% | ||
| Current Ratio | 3.61 | ||
| Quick Ratio | 3.09 | ||
| Altman-Z | 3.89 |
F-Score7
WACC7.1%
ROIC/WACC1
Cap/Depr(3y)78.4%
Cap/Depr(5y)95.94%
Cap/Sales(3y)7.97%
Cap/Sales(5y)9.87%
Profit Quality(3y)273.85%
Profit Quality(5y)189.74%
High Growth Momentum
Growth
EPS 1Y (TTM)3.45%
EPS 3Y-7.11%
EPS 5Y8.09%
EPS Q2Q%10.91%
EPS Next Y7.19%
EPS Next 2Y8.36%
EPS Next 3Y9.1%
EPS Next 5Y9.82%
Revenue 1Y (TTM)0.66%
Revenue growth 3Y-4.22%
Revenue growth 5Y5.32%
Sales Q2Q%2.36%
Revenue Next Year5.1%
Revenue Next 2Y5.92%
Revenue Next 3Y8.59%
Revenue Next 5Y8.35%
EBIT growth 1Y10.42%
EBIT growth 3Y-32.77%
EBIT growth 5Y-8.55%
EBIT Next Year55.59%
EBIT Next 3Y22.21%
EBIT Next 5Y19.16%
FCF growth 1Y69.33%
FCF growth 3Y5.12%
FCF growth 5Y55.1%
OCF growth 1Y46.6%
OCF growth 3Y1.77%
OCF growth 5Y15.28%